Eisenmenger Syndrome: Causes, Pathophysiology, Diagnosis, Imaging, Treatment, and Prognosis

on

 

Introduction

Eisenmenger syndrome (ES) represents one of the most severe complications of congenital heart disease, characterized by the reversal of an initial left-to-right shunt into a right-to-left shunt due to progressive pulmonary vascular remodeling and pulmonary arterial hypertension (PAH). This syndrome leads to systemic hypoxemia, cyanosis, and a cascade of multi-organ complications. Although increasingly rare in high-resource countries due to early detection and correction of congenital heart defects, Eisenmenger syndrome remains an important cause of morbidity and mortality worldwide.

This article will provide an in-depth discussion of Eisenmenger syndrome, integrating radiologic evidence, case study material, clinical features, treatment strategies, and prognosis.

Case Study: A 58-Year-Old Woman with Eisenmenger Syndrome

A 58-year-old woman presented with chronic progressive dyspnea over several years, worsening in recent months. A chest X-ray and contrast-enhanced CT were obtained.

[Figure 1] Chest A-P: Severe left cardiac enlargement occupying most of the left thorax. Pulmonary fields are relatively clear. Mediastinal enlargement suggests cardiac pathology.


[Figure 2] Axial Chest CT (contrast-enhanced): Shows atrial septal defect with severe enlargement of the right atrium and left atrium. The pulmonary artery is dilated, consistent with pulmonary hypertension. Contrast demonstrates right-to-left shunt reversal.

[Figure 3] Coronal Chest CT (contrast-enhanced): Confirms marked pulmonary artery dilation, shunt reversal, and cardiac remodeling.

Diagnosis: Eisenmenger Syndrome.

Etiology and Cause

Eisenmenger syndrome develops as a late complication of uncorrected congenital heart defects that initially produce a significant left-to-right shunt:

  • Ventricular septal defect (VSD) – the most common underlying lesion.

  • Atrial septal defect (ASD).

  • Patent ductus arteriosus (PDA).

  • Atrioventricular septal defects (AVSD).

Initially, these defects allow oxygenated blood from the systemic circulation to enter the pulmonary circuit, resulting in volume and pressure overload of the pulmonary vasculature. Over time, pulmonary vascular resistance (PVR) rises due to intimal hyperplasia, medial hypertrophy, and vascular obliteration. When pulmonary arterial pressure equals or exceeds systemic levels, the shunt reverses, leading to deoxygenated blood entering systemic circulation.

Pathophysiology

  1. Initial Phase: Large left-to-right shunt → pulmonary overcirculation.

  2. Progression: Chronic shear stress and endothelial dysfunction → remodeling of pulmonary vasculature → pulmonary arterial hypertension (PAH).

  3. Reversal Phase: Pulmonary vascular resistance exceeds systemic resistance → shunt reverses to right-to-left.

  4. Clinical Consequence: Hypoxemia, cyanosis, erythrocytosis, increased risk of stroke, paradoxical embolism, and multi-organ dysfunction.

Epidemiology

  • Once common, ES is now rare in developed countries due to early pediatric screening and corrective surgery.

  • Still prevalent in regions with limited healthcare access, where congenital heart defects remain untreated.

  • Typically diagnosed in adolescents or young adults, though late diagnoses (such as the 58-year-old case presented) still occur.

  • Incidence: <5% of congenital heart disease patients in high-income nations progress to ES.

Clinical Presentation

Patients with Eisenmenger syndrome commonly exhibit:

  • Dyspnea on exertion (progressive).

  • Cyanosis (bluish discoloration of skin/mucous membranes).

  • Clubbing of fingers and toes.

  • Fatigue and exercise intolerance.

  • Palpitations and syncope.

  • Hemoptysis due to rupture of hypertensive pulmonary vessels.

  • Polycythemia due to chronic hypoxemia (leading to hyperviscosity symptoms: headache, dizziness, stroke risk).

Imaging Features

Radiologic evaluation is critical for diagnosis.

  • Chest X-ray ([Figure 1]):

    • Marked cardiomegaly, especially of the right heart chambers.

    • Dilated pulmonary arteries.

    • Clear lung fields but reduced peripheral vascular markings.

  • Contrast-Enhanced CT ([Figure 2], [Figure 3]):

    • Enlarged pulmonary trunk and central pulmonary arteries.

    • Atrial septal defect with contrast flow from right-to-left atrium (shunt reversal).

    • Dilated right atrium, right ventricle, and pulmonary arteries.

    • Surgical clips and Swan-Ganz catheter in situ (in this case).

  • Echocardiography: Demonstrates septal defects and shunt direction. Bubble contrast echo confirms right-to-left passage.

  • MRI: Provides functional data on shunt flow and pulmonary vascular resistance.

Differential Diagnosis

Conditions with pulmonary hypertension must be differentiated:

  • Chronic thromboembolic pulmonary hypertension (CTEPH).

  • Idiopathic pulmonary arterial hypertension (IPAH).

  • Pulmonary veno-occlusive disease.

  • Drug-induced PAH (amphetamine, fenfluramine).

  • HIV-related PAH.

  • Connective tissue disorders (scleroderma).

Treatment

Management is primarily palliative; prevention via early congenital heart defect repair is key.

  1. Medical therapy:

    • Oxygen therapy (limited benefit).

    • Diuretics (fluid overload).

    • Anticoagulants (cautiously, bleeding risk is high).

    • Antiarrhythmic drugs.

    • Vasodilators (e.g., endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogs) – some evidence of symptomatic benefit.

  2. Surgical/Interventional therapy:

    • Heart-lung transplantation – definitive but limited by donor availability.

    • Surgical closure of the shunt is contraindicated once Eisenmenger syndrome is established (worsens PAH).

  3. Supportive care:

    • Avoidance of dehydration (reduces risk of hyperviscosity complications).

    • Iron supplementation if deficient.

    • Regular phlebotomy is only performed in cases of symptomatic hyperviscosity.

    • Preventive measures: avoid pregnancy (high maternal mortality), avoid high altitudes.

Prognosis

  • Median survival: 20–30 years after diagnosis, though some patients live into their 50s–60s.

  • Prognosis depends on: type of underlying defect, the degree of pulmonary hypertension, and comorbidities.

  • Complications: sudden cardiac death, stroke, cerebral abscess, hemoptysis, progressive right heart failure.

Quiz Section

Question 1. The main abnormality on [Figure 1] Chest A-P lies within the lungs.

A) True

B) False

Question 2. Which heart chamber is enlarged on [Figure 2] CT?

A) Right atrium

B) Left atrium

C) Right ventricle

D) Left ventricle

E) All four chambers

Question 3. Which type of septal defect is typically associated with Eisenmenger syndrome?

A) Muscular VSD

B) Sinus venosus ASD

C) Membranous VSD

D) Coronary sinus defect

Question 4. In Eisenmenger syndrome, pulmonary arterial pressure eventually:

A) Remains below systemic pressure

B) Equals or exceeds systemic pressure

C) Never changes

Question 5. Which treatment is contraindicated in Eisenmenger syndrome?

A) PDE-5 inhibitors

B) Endothelin receptor antagonists

C) Surgical shunt closure

D) Heart-lung transplantation

Answer & Explanation

1. Answer: (B) False. Explanation: The chest radiograph shows marked cardiomegaly (predominantly left-sided cardiac enlargement) and enlarged central pulmonary vasculature, while the lung fields are relatively clear. Because the abnormality is characterized by an enlarged cardiac silhouette and mediastinal structures rather than a focal pulmonary parenchymal lesion, the primary abnormality is located within the heart/mediastinum, rather than the lungs.

2. Answer: (A) Right atrium (with left atrium also enlarged).
Explanation: Contrast-enhanced CT demonstrates marked dilatation of the central right-sided cardiac structures, particularly the right atrium, reflecting chronic right-heart pressure/volume overload due to pulmonary hypertension and shunting. In Eisenmenger physiology, the right-sided chambers (right atrium and right ventricle) commonly dilate; the left atrium may be secondarily enlarged depending on anatomy and chronic volume shifts, but the right atrium is most prominent on these images.

3. Answer: (c) Membranous ventricular septal defect (VSD) — large VSDs in general.
Explanation: Eisenmenger syndrome most often arises from large, uncorrected left-to-right shunts that chronically overcirculate the pulmonary vasculature. Large VSDs (frequently perimembranous/membranous) are common culprits because they create a high-flow, high-pressure pulmonary circulation early in life; over the years, that increased flow stimulates pulmonary vascular remodeling and eventual reversal of the shunt.

4.  Answer: (B) Equals or exceeds systemic pressure. Explanation: Eisenmenger syndrome develops when long-standing left-to-right cardiac shunts (such as VSD, ASD, or PDA) chronically overload the pulmonary circulation. Over time, persistent high flow and pressure lead to pulmonary vascular remodeling (intimal hyperplasia, medial hypertrophy, fibrosis). This process progressively increases pulmonary vascular resistance (PVR). Eventually, the pulmonary arterial pressure rises to match or surpass systemic arterial pressure, eliminating the original left-to-right gradient. At this stage, the shunt reverses direction (right-to-left), resulting in systemic hypoxemia and cyanosis.

5. Answer: (C) Surgical closure of the intracardiac shunt is contraindicated.
Explanation: Closing a long-standing shunt in the presence of fixed, high pulmonary vascular resistance forces the right ventricle to pump entirely against the elevated pulmonary afterload without the decompression pathway the shunt provided. This abrupt hemodynamic change can precipitate right ventricular failure and worsen clinical status. Therefore, established Eisenmenger patients are managed medically or considered for transplantation rather than shunt closure; targeted pulmonary vasodilator therapy may be used selectively under specialist care.

References

[1] H. Basit, T.J. Wallen, B.N. Sergent, “Eisenmenger Syndrome,” StatPearls, Treasure Island, FL: StatPearls Publishing, 2020.
[2] C. Favoccia, A.H. Constantine, S.J. Wort, K. Dimopoulos, “Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease,” Expert Rev Cardiovasc Ther, vol. 17, no. 6, pp. 449–459, 2019.
[3] H. Nashat, C. Montanaro, W. Li, et al., “Atrial septal defects and pulmonary arterial hypertension,” J Thorac Dis, vol. 10, Suppl. 24, pp. S2953–S2965, 2018.
[4] R. Sheehan, J.K. Perloff, M.C. Fishbein, D. Gjertson, D.R. Aberle, “Pulmonary neovascularity: A distinctive radiographic finding in Eisenmenger syndrome,” Circulation, vol. 112, no. 18, pp. 2778–2785, 2005.
[5] M.A. Galiè, N. Humbert, J. Vachiery, et al., “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension,” Eur Heart J, vol. 37, no. 1, pp. 67–119, 2016.
[6] D. Hopkins, R. Leonard, “Eisenmenger syndrome: clinical aspects and management strategies,” Heart, vol. 92, no. 12, pp. 1747–1752, 2006.
[7] T. Dimopoulos, A. Diller, G.P. Kolb, et al., “Management of Eisenmenger syndrome: current evidence and future perspectives,” Curr Opin Cardiol, vol. 33, no. 5, pp. 594–601, 2018.
[8] S. Warnes, “Adult congenital heart disease: Eisenmenger syndrome and pulmonary hypertension,” Prog Cardiovasc Dis, vol. 59, no. 3, pp. 282–292, 2017.

Comments

Post a Comment